In a breakthrough discovery, Indian scientists have developed a unique, distinctive way through the nose to deliver medicines for tuberculosis directly to the brain. The feat was achieved by the researchers from the Institute of Nano Science and Technology in Mohali - an autonomous institute of the Department of Science and Technology. Also known as tuberculous meningitis – the condition is caused by the seeding of the meninges with the bacilli of MTB and is characterized by the inflammation of the membranes around your brain or spinal cord.
According to statistics, around one-third of the world’s population is presumed to be infected with MTB – a life-threatening and fatal disease. India accounts for about 25 per cent of the global TB burden, with an estimated incidence of 2.77 million in 2022.
How does the nose-to-brain drug delivery work? Scientists said the delivery of the novel nose-to-brain drug utilizes the olfactory and trigeminal nerve pathways in the nasal cavity and effectively bypasses the challenging blood-brain barrier. Even though traditional TB treatments involve high doses of oral drugs, experts say they mostly fail to achieve effective concentrations in the cerebrospinal fluid as the BBB limits the medicines from entering the brain. To counter this, the scientists used nanoparticles made of chitosan - a fibrous substance that might reduce how much fat and cholesterol the body absorbs from foods - which bypassed the BBB and delivered TB medicines direct.